ADVANCED RNA TECHNOLOGIES, LLC

Boulder, CO · Biotech · Private

Chemically modified siRNA conjugates for long-acting ocular gene silencing therapeutics

advirna.com →
Grants
$1.1M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · High throughput RNAi based functional genomics in primary cells and in vivo$572,600
Federal grantDepartment of Health and Human Services · Phase I · "Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer"$231,500
Federal grantDepartment of Health and Human Services · Phase I · Chemically modified siRNA drugs for ocular disease$294,022
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3254Cellarcus Biosciences, Inc.——
3255General Beverage Consulting & Management, Inc.—$350K
3256Antiger Therapeutics Inc.——
3257ADVANCED RNA TECHNOLOGIES, LLC——
3258RESEARCH AND DIAGNOSTIC SYSTEMS, INC.——
3259CAVALRY BIOSCIENCES INC——
3260NeuroFx, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.